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Abstract 14 
Objective 15 
Passive heating (PH) has begun to gain research attention as an alternative therapy for cardio-16 
metabolic diseases. Whether PH improves glycaemic control in diabetic and non-diabetic 17 
individuals is unknown. This study aims to review and conduct a meta-analysis of published 18 
literature relating to PH and glycaemic control.  19 
Methods 20 
Electronic data sources, PubMed, Embase and Web of Science from inception to July 2018 were 21 
searched for randomised controlled trials (RCT) studying the effect of PH on glycaemic control in 22 
diabetic or non-diabetic individuals. To measure the treatment effect, standardised mean 23 
differences (SMD) with 95 % confidence intervals (CI) were calculated.  24 
Results 25 
Fourteen articles were included in the meta-analysis. Following a glucose load, glucose 26 
concentration was greater during PH in non-diabetic (SMD 0.75, 95 % CI 1.02 to 0.48, P < 0.001) 27 
and diabetic individuals (SMD 0.27, 95 % CI 0.52 to 0.02, P = 0.030). In non-diabetic individuals, 28 
glycaemic control did not differ between PH and control only (SMD 0.11, 95 % CI 0.44 to -0.22, 29 
P > 0.050) and a glucose challenge given within 24 hours post-heating (SMD 0.30, 95 % CI 0.62 30 
to -0.02, P > 0.050). 31 
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Conclusion 32 
PH preceded by a glucose load results in acute glucose intolerance in non-diabetic and diabetic 33 
individuals. However, heating a non-diabetic individual without a glucose load appears not to 34 
affect glycaemic control. Likewise, a glucose challenge given within 24 hours of a single-bout of 35 
heating does not affect glucose tolerance in non-diabetic individuals. Despite the promise PH may 36 
hold, no short-term benefit to glucose tolerance is observed in non-diabetic individuals. More 37 
research is needed to elucidate whether this alternative therapy benefits diabetic individuals.  38 
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Introduction 39 
Frequent passive heating (PH), often referred to as Waon therapy, hot-tub therapy or thermal 40 
therapy, may provide health benefits for those who are in diseased and non-diseased states [1–6]. 41 
Chronic use of Finnish saunas (80 °C – 100 °C air, < 20 % relative humidity) is associated with a 42 
reduced risk of dementia, stroke, respiratory disease, hypertension, fatal cardiovascular and all-43 
cause mortality events [7–11]. The mechanisms responsible for how PH maintains health in those 44 
free of disease and improves health in diseased conditions are not completely clear. Current 45 
evidence suggests PH elicits improvements in shear patterns (increase in antegrade shear), 46 
microvascular function (endothelial-dependent), lipid profiles, reduced arterial stiffness and blood 47 
pressure, as well as reduced heart rate and deep body temperature during heat stress [12–21]; 48 
responses that are also evident, albeit to a greater extent, following regular physical activity.  49 
 50 
The therapeutic effects of PH on those experiencing poor glycaemic control has not been 51 
thoroughly investigated in humans. Globally, it was estimated 422 million adults aged over 18 52 
years were living with diabetes in 2014 [22], equating to ~8.5 % of the world’s population. Type 53 
2 diabetes mellitus (T2DM), accounting for ~90 % of individuals with diabetes, is associated with 54 
high blood glucose, insulin resistance and increased insulin secretion [23,24]. Glycogen stored in 55 
the liver can be released into the bloodstream as blood sugar (glycogenolysis), with cells able to 56 
metabolise the glucose or store for later needs. This process maintains blood sugar in between 57 
meals but is not as tightly regulated in those with diabetes and poor glycaemic control. In these 58 
compromised conditions, blood glucose rises due to the insulin insensitivity, resulting in more 59 
insulin being released. T2DM is a progressive disease, with prolonged untreated states leading to 60 
pancreatic beta-cell damage and loss of insulin secretion [24]. Lifestyle interventions (e.g. diet 61 
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assessment, promotion of physical activity) may attenuate or even reverse the complications 62 
associated with T2DM [25,26]. Despite the benefits associated with these interventions, adherence 63 
is often poor and, in some cases, not possible. Alongside lifestyle interventions, drug therapy is 64 
often prescribed but may carry unwanted side effects [27]. 65 
 66 
Non-pharmaceutical interventions, such as PH, may benefit people with diabetes and those with 67 
poor glycaemic control. Supporting this viewpoint, Hooper [6] invited eight participants with 68 
T2DM to sit in warm water (38 °C – 41 °C) for 30 minutes a day, six days a week over three 69 
weeks. At the end of the three weeks, fasting glucose was reduced, but more importantly, 70 
haemoglobin A1c (HbA1c) was reduced by 1 %. Changes in HbA1C of the 1 % magnitude reported 71 
are clinically important as they are associated with a 21 % reduction in all-cause diabetes-related 72 
deaths [28]. Notably, however, no control group was included in this study and differences in age, 73 
sex and disease severity amongst participants potentially confound the results. 74 
 75 
Resting in warm environments may induce hormonal changes that may influence glycaemic 76 
control [4,29]. While insulin concentrations may not change during PH, thyroid hormone, growth 77 
hormone, noradrenaline and adrenaline concentrations may rise to elicit greater concentrations of 78 
blood glucose [30–32]. Acutely raising blood glucose concentrations is not of benefit but PH may 79 
elicit other changes to reduce the blood glucose concentration. Muscle temperature and blood flow 80 
may rise if heating is sufficient, which may acutely promote muscle glucose uptake [33,34]. The 81 
mechanisms responsible for the chronic reduction in fasting glucose and HbA1C may be multi-82 
factorial, but heat shock proteins (HSP) may play a pivotal role [35]. Upon physiological stress 83 
(e.g. heat, hypoxia, cancer) there is an increase in the amount of unfolded and misfolded proteins, 84 
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causing cell damage [36–38]. The physiological stress is accompanied by a heat shock response, 85 
which triggers the release of HSP. The increased number of HSP available help facilitate correct 86 
folding of proteins, thus preventing cell damage. Both human and murine diabetic models are 87 
characterised by low intracellular (i) and high extracellular (e) HSP levels [39–45], promoting a 88 
pro-inflammatory state that reduces insulin sensitivity [46,47]. iHSP has direct protective effects 89 
whereas high eHSP is linked with insulin resistance [48,49]. Restoration of iHSP levels in diabetic 90 
models and subsequent favourable glycaemic control are mediated, in part, through reductions in 91 
inflammatory cytokines, c-Jun N-terminal kinase and IkappaB kinase, both associated with the 92 
inhibition of insulin signalling [50,51]. Importantly, PH has been shown to increase iHSP levels 93 
in diabetic and obese human and murine models [39,52,53]. 94 
 95 
Considering these findings, it would seem prudent to study PH and its effect on glycaemic control 96 
further. Indeed, reviews have highlighted how PH may benefit individuals with diabetes or those 97 
who are insulin resistant [27,35,45,46,54–58], but to date, there is no systematic search, review 98 
and meta-analysis of PH and glycaemic control in diabetic and non-diabetic individuals. Therefore, 99 
the purpose of this study was to review and conduct a meta-analysis of published literature relating 100 
to PH and glycaemic control. 101 
  102 
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Methods 103 
Search strategy 104 
An electronic literature search was conducted in July 2018 using PubMed, Embase, and Web of 105 
Science. Searches were performed using Boolean operators and the following key terms and their 106 
combinations: glucose, insulin, diabetes, passive heating, sauna, thermal therapy, warm water, 107 
warm air, thermotherapy, and hot water immersion. The reference lists of all included studies were 108 
also examined to identify potentially relevant data sets that were not found in the original search 109 
(Fig 1).  110 
Study inclusion and exclusion criteria 111 
Studies were included in the review where: 1) a PH intervention, defined as any technique designed 112 
to increase body temperature using non-exercise models, was applied; 2) the experimental design 113 
included a non-heating control trial; 3) at least one primary outcome measure (i.e. glucose or 114 
insulin) was reported; 4) participants were human adults (i.e. aged ≥18 years), and 5) data were 115 
published in a peer-reviewed journal. There were no restrictions applied to the PH mode (e.g. water 116 
or air), exposure duration, participant sex, health status or study setting. Studies involving exercise 117 
in combination with PH were excluded. 118 
Selection criteria 119 
Titles and abstracts returned by the search strategy were screened independently by two authors 120 
(MM, GM) to remove those that were outside of the scope of the review. Full-text of papers that 121 
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potentially met the review inclusion criteria were obtained. Disagreements between authors 122 
regarding study inclusion were resolved by consensus or a third party (AH). 123 
Data extraction 124 
A customised form was used to extract relevant data on methodological design independently, 125 
eligibility criteria, interventions, participant descriptors, comparisons and outcome measures by 126 
two authors (MM, AH). The outcome measures extracted included 1) blood glucose and insulin; 127 
and 2) complications or adverse effects experienced attributable to the intervention. The authors 128 
of original investigations were contacted via email, as required, to clarify any queries relating to 129 
data or study characteristics as required. Any disagreement between the review authors extracting 130 
data was resolved by consensus or a third party (GM). 131 
Risk of bias assessment 132 
Risk of bias assessment was independently conducted in accordance with the Cochrane Handbook 133 
for Systematic Reviews of Interventions [59] by two authors (MM, AH). Potential sources of bias 134 
were classified as high, low or unclear in the areas of sequence generation, allocation concealment, 135 
blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, 136 
selective outcome reporting, and other bias. These outcomes were visually summarised (Fig 2), 137 
with any disagreement between the authors’ interpretation resolved by consensus or a third party 138 
(GM). 139 
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Statistical analyses 140 
To measure the treatment effect, standardised mean differences (SMD) with 95 % confidence 141 
intervals (CI) were calculated and analysed using a random effects model. Missing data prompted 142 
an email request to the study authors seeking this data and/or clarification as to why data were 143 
missing. The absence of standard deviations that could not be sourced from authors were calculated 144 
from available statistics as per Higgins and Green [59]. Further, where necessary, data were 145 
manually extracted from figures using WebPlotDigitizer [60]. Heterogeneity between comparable 146 
trials was evaluated using the I2 statistic. Values of I2 were interpreted using the following scale 147 
[59]: 0% to 40%, might not be important; 30% to 60%, moderate heterogeneity; 50% to 90%, 148 
substantial heterogeneity; and 75% to 100%, considerable heterogeneity.  149 
 150 
 151 
  152 
10 
 
Results 153 
The search strategy identified a total of 2038 records (Fig 1). We also found nine potentially 154 
eligible studies from additional reference searches in these papers. Following removal of 155 
duplicates (n = 988), 1059 titles and abstracts were screened which resulted in 49 full-text articles 156 
being retrieved for eligibility. Articles were included in full-text screening if the abstract discussed 157 
PH in humans relating to either non-diabetic or diabetic individuals. After full-text screening, 158 
another 35 articles were excluded, mostly due to no relevant primary outcome or inappropriate 159 
control trial. Consequently, 14 articles were included in the final meta-analysis. 160 
 161 
 162 
Fig 1. PRISMA flowchart 163 
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Study characteristics 164 
Table 1 shows the characteristics of the included studies. The sample size varied from six 165 
[30,61,62] to 32 [63]. In two studies, both non-diabetic and diabetic individuals were examined 166 
[63,64], while nine studies focused on non-diabetic individuals [30,62,65–71] and three studies 167 
focused on diabetic individuals [61,72,73]. The studies using diabetic participants described their 168 
cohort as non-insulin-dependent [63], insulin-dependent [61,72], type 1 [73] and T2DM [64]. The 169 
participants described as non-insulin-dependent received treatment with small doses of oral 170 
sulfonylureas [63]. The studies utilising insulin-dependent diabetics were described as receiving 171 
between 20 U to 27 U of intermediate or intermediate plus rapid-acting insulin in one of two 172 
injections per day [61,72], or 26 U to 56 U of long or long plus rapid-acting insulin in one or two 173 
injections per day [73]. The T2DM participants were taking Metformin [64]. 174 
In four studies, both male and female individuals were examined [63,64,67,71], while ten studies 175 
examined males only [30,61,62,65,66,68–70,72,73]. The mean age of the participants varied 176 
between 19 years [73] and 56 years [63].  177 
 178 
Regarding methodology, all participants were fasted, except one study [68]. A glucose load (meal 179 
or glucose solution) was given before PH and control trials in seven studies using non-diabetic 180 
individuals [62,63,65–67,69,71]. A glucose load and insulin were given before PH and control 181 
trials in three studies using diabetic individuals [61,72,73]. No glucose or insulin was given before 182 
PH and control in four experiments [30,66,68,70]. Three experiments included data where a 183 
glucose load was given immediately [30], 120 minutes [30] or 24-hours post-heating [64]. Eleven 184 
studies used air (31 °C to 85 °C) to heat participants [61–63,65–67,69–73], while two studies used 185 
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water (39 °C – 40 °C) [30,64], and the other used a mix of water (43 °C) and then air (44 °C) [68]. 186 
Heating duration varied from 30 minutes [30,62] to 240 minutes [61].  187 
 188 
All studies measured glucose concentration from venous blood samples. Insulin concentration was 189 
measured in five studies using non-diabetic individuals during PH and control trials following a 190 
glucose load [62,65–67,69].  191 
Risk of bias 192 
Risk of bias via the Cochrane Collaboration’s tool indicated that most of the information was from 193 
studies with low or unclear bias (Fig 2). Despite not being able to blind participants to a hot 194 
environment, performance bias and detection bias was low for all studies as participants were 195 
considered unable to change their glucose concentration consciously. Other biases included 196 
unclear or inappropriate statistical analyses and unclear handling, storage and analyses of blood 197 
samples. 198 
 199 
 200 
Fig 2. Risk of bias summary 201 
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Meta-analysis outcome 202 
Glucose concentration 203 
A summary of individual studies and meta-analysis for glycaemic control following a glucose load 204 
are shown in Fig 3 and Fig 4. Fasting glucose concentration did not differ between control and PH 205 
in both non-diabetic (Fig 3) and diabetic individuals (Fig 4). Compared with control, glucose 206 
concentration was greater after 20 – 30 minutes of PH in non-diabetic individuals, which was a 207 
consistent observation at 40 – 60 minutes and 120 minutes of PH (Fig 3). In diabetic individuals, 208 
glycaemic control did not differ at any time point between PH and control trials, but the pooled 209 
overall effect was statistically significant, highlighting the potentially greater glucose 210 
concentration during PH (Fig 4). 211 
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 212 
Fig 3. Effects of control and passive heating trials on glucose concentration (mmol/L) in non-213 
diabetic individuals following a glucose load. 214 
ND, non-diabetic; D, diabetic; norm, normal weight; over, overweight. 215 
 216 
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 217 
 218 
Fig 4. Effects of control and passive heating trials on glucose concentration (mmol/L) in diabetic 219 
individuals following a glucose load. 220 
ND, non-diabetic; D, diabetic; norm, normal weight; over, overweight. 221 
 222 
When analysing data from experiments that did not administer a glucose load, glycaemic control 223 
did not differ between PH and control trials (Fig 5). Similarly, glycaemic control did not differ 224 
between PH and control trials when a glucose challenge was administered post-heating (Fig 6). 225 
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 226 
Fig 5. Effects of control and passive heating trials on glucose concentration (mmol/L) in non-227 
diabetic individuals. 228 
 229 
 230 
 231 
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Fig 6. Effects of a glucose load on glucose concentration (mmol/L) after control and passive  232 
heating trials in non-diabetic individuals. 233 
 234 
 235 
Insulin concentration 236 
A summary of individual studies and meta-analysis of insulin concentration following a glucose 237 
challenge is shown in Fig 7. At each time point, insulin concentration was similar between control 238 
and PH. 239 
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 240 
 241 
Fig 7. Effects of control and passive heating trials on insulin concentration (μU/mL) in non-242 
diabetic individuals following a glucose load. 243 
 244 
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Table 1. Characteristics of included studies 245 
First 
author, 
year 
Populationa Fasted? Glucose load? Insulin 
given? 
Time between glucose/insulin 
and heating (minute) 
Control 
protocol 
Passive 
heating 
protocol 
Akanji 
1987  
22 non-diabetic 
• 6 males/4 females, normal 
weight, 47(13) years of age 
• 6 males/6 females, overweight, 
43(13) years of age 
Yes 960 kcal meal No 0  23 °C air, 120 
minutes 
33 °C air,  
120 minutes 
5 males/1 female non-diabetic, 
normal weight, 19-57 years of age 
Yes 75 g of glucose  No 0  23 °C air, 120 
minutes 
33 °C air,  
120 minutes 
Akanji 
1991 
16 non-diabetic 
• 4 male/4 female, normal 
weight, 45(6) years of age 
• 4 male/4 female, overweight, 
42(6) years of age 
16 diabetic 
• 4 male/4 female, normal 
weight, 54(11) years of age 
• 4 male/4 female, overweight, 
56(11) years of age 
Yes 75 g of glucose No 0  23 °C air, 120 
minutes 
33 °C air,  
120 minutes 
Dumke 
2015 
11 males non-diabetic, normal 
weight, 22(3) years of age 
Yes Glucose given at 
1.8 g·kg–1 of body 
mass 
No 0  22 °C air, 180 
minutes 
43 °C air, 180 
minutes 
Faure 
2016  
Study A: 10 males, non-diabetic, 
normal weight, 21(2) years of age  
Yes 62 kcal meal No Given 30 minutes post-heating 22 °C for 40 
minutes 
31 °C for 40 
minutes 
Study B: 12 males, non-diabetic, 
normal weight, 20(2) years of age  
Yes 75 g of glucose No 0 22 °C air, 180 
minutes 
31 °C air, 180 
minutes 
Frayn 
1989 
4 males/2 females, non-diabetic, 
normal weight, 20–40 years of age 
Yes 75 g of glucose  No 0 23 °C air, 120 
minutes 
33 °C air,  
120 minutes 
Jezova 
1998  
 
9 males, non-diabetic, normal 
weight, 23–25 years of age 
Yes No No NA 22–24 °C air, 
45 minutes 
53 °C sauna, 
45 minutes 
aAge given in mean (SD); for missing mean (SD), the range is specified. Participants distributed by sex if data were available. Normal weight defined as a body 246 
mass index ≤ 25.  247 
  248 
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Table 1. Continued 249 
First 
author, year 
Populationa Fasted
? 
Glucose load? Insulin given? Time between 
glucose and 
heating  
Control protocol Passive heating 
protocol 
Jurcovicova 
1980  
Experiment 1: 6 males, non-
diabetic, normal weight, 23–27 
years of age 
Yes Glucose given 
at 1 g·kg–1 of 
body mass 
No Given 
immediately 
following 
heating 
30 °C water to 
neck, 30 minutes 
40 °C water to 
neck, 30 minutes 
Experiment 2: 6 males, non-
diabetic, normal weight, 23–27 
years of age 
Yes 100 g of 
glucose 
No Given 90 
minutes post-
heating 
30 °C water to 
neck, 30 minutes 
40 °C water to 
neck, 30 minutes 
Koivisto 
1980 
8 males, diabetic, normal weight, 
34(11) years of age 
Yes 430 kcal meal 10 U Actrapid & 
6-40 U Monotard 
given immediately 
before meal. 
60 minutes 22 °C air, 60 
minutes 
85 °C sauna, 60 
minutes 
Koivisto 
1981 
6 males, diabetic, normal weight, 
29(7) years of age 
Yes 280 kcal meal 6 U Actrapid 
given immediately 
before meal. 
0  20 °C air, 240 
minutes 
35 °C air, 240 
minutes 
Koivisto 
1983 
8 males, diabetic, normal weight, 
19(8) years of age 
Yes 430 kcal meal 14 U Semilente 
given immediately 
before meal. 
60 minutes 22 °C air, 60 
minutes total 
85 °C sauna, 60 
minutes total 
Linnane 
2004 
7 males, non-diabetic, normal 
weight, 27(8) years of age 
No No No NA Lay down in 
empty bath for 15 
minutes then sat 
in 20 °C air for 30 
minutes 
43 °C water to 
neck for ~16 
minutes, then sat 
in 44 °C air for 
~30 minutes 
Moses 1997 
7 males, non-diabetic, normal 
weight, 24(4) years of age 
Yes 75 g of glucose No 0  25 °C air, 120 
minutes 
35 °C air, 120 
minutes 
Rivas 2016 
• 2 male/7 female non-diabetic, 
overweight, 41(14) years of 
age 
• 3 male/6 female diabetic, 
overweight, 50(12) years of 
age 
Yes 75 g of glucose No Given 24-hours 
post-heating 
24 °C air, 120 
minutes 
39 °C water, 120 
minutes 
Tatar 1985 
6 males, non-diabetic, normal 
weight, 22–24 years of age 
Yes 100 g of 
glucose  
No 15 minutes 23 °C air, 30 
minutes 
85 °C sauna for 
30 minutes 
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aAge given in mean (SD). For missing mean (SD), the range is specified. Participants distributed by sex if data were available. Normal weight defined as a body 250 
mass index ≤ 25.  251 
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Discussion 252 
The primary aim of this meta-analysis was to investigate the effect of PH on glycaemic control in 253 
diabetic and non-diabetic individuals. Collectively, the meta-analysis showed PH resulted in a 254 
greater glucose concentration in diabetic and non-diabetic individuals (Fig 3 and Fig 4). In 255 
contrast, glycaemic control does not differ between PH and control trials without a glucose load 256 
(Fig 5). Finally, no favourable glycaemic control was observed following a glucose challenge 257 
within 24 hours of a single bout of PH (Fig 6). 258 
 259 
Hormone changes may, in part, affect blood glucose concentrations during PH [4,29]. Considering 260 
glycaemic control does not differ between PH and control trials conducted without a glucose 261 
challenge (Fig 5) and insulin concentration does not differ during PH preceded with a glucose load 262 
(Fig 7), it is likely other factors may be at play. Arterialisation of venous blood [67] may be another 263 
contributing factor. Arterial blood glucose is consistently greater than venous blood glucose, but 264 
the difference between a vein in a heated hand and arterial samples is substantially smaller [74] 265 
owing to the opening of the arterio-venous anastomoses. This phenomenon presents a problem for 266 
oral glucose tolerance tests conducted in varying environments as the sampling technique may be 267 
a limiting factor. No study included in this meta-analysis used the heated hand technique [75]. 268 
Future studies should be mindful that arterialisation of venous blood may provide a methodological 269 
limitation to venous blood glucose sampling when comparing PH and thermoneutral trials. Heating 270 
the hand in both thermoneutral and PH trials may circumvent this limitation. 271 
 272 
In contrast to non-diabetic individuals, glycaemic control was similar in PH and control trials at 273 
individual time points in diabetic individuals (Fig 4). However, the pooled overall effect indicated 274 
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PH may elicit greater glucose concentrations. It is possible the reduced glucose extraction due to 275 
insulin resistance is partly responsible; thus arterialisation of venous blood yields minimal 276 
difference. Nevertheless, differences in hormonal responses influencing glucose output and uptake 277 
cannot be ruled out. 278 
 279 
Providing a glucose challenge post-heating may be a more appropriate research design considering 280 
hormonal changes and arterialisation of venous blood may confound outcomes during PH. Glucose 281 
tolerance tests are also regularly conducted post-exercise, highlighting an insulin sensitising effect 282 
improving glycaemic control that is a relatively short-lived phenomenon (<48 hours) [76]. Limited 283 
studies were available for meta-analysis of post-heating glucose tolerance, with PH showing no 284 
beneficial effect on glucose tolerance immediate [30], 120 minutes [30] and 24 hours post-heating 285 
[64] in non-diabetic individuals. Rivas et al. [64] did also measure glucose tolerance post-heating 286 
in T2DM individuals but, again, found PH not to influence glycaemic control. It is possible, as the 287 
author's state [64], they may have missed the window for improved insulin sensitivity or 288 
participant’s continued medication may have influenced the glycaemic response. It is clear more 289 
work is needed with diabetic individuals to investigate glycaemic control following a single-bout 290 
of PH. 291 
 292 
Our systematic search of the literature found no chronic randomised control trials investigating the 293 
effect of PH on glycaemic control in people with diabetes. Considering Hooper [6] provided 294 
evidence of the benefits of PH for those with T2DM nearly 20 years ago, it is surprising to find no 295 
other chronic study has been conducted. In the meantime, pharmaceutical agents have been 296 
developed to stimulate HSP production, replicating the response observed during PH and exercise 297 
24 
 
[27,35,38,54]. Aside from Hooper [6], only three studies have investigated the effect of chronic 298 
PH in individuals with diabetes and other diseased states [15,77]. Specifically, PH (20 minutes, 3 299 
days per week, over 3 months) improved perceived quality of life in people with T2DM [77], while 300 
Imamura et al., [15] reported fasting glucose was reduced with PH (45 minutes, 7 days a week, 301 
over 2 weeks) in those with coronary risk factors (e.g. obesity, diabetes, hypertension). However, 302 
Masuda [21] reported no change in fasting glucose associated with PH (45 minutes, 7 days a week, 303 
over 2 weeks) in those with coronary risk factors. The reason for the discrepancy between the latter 304 
two studies is not clear. 305 
 306 
Favourable glycaemic control following PH was initially attributed to an increased muscle blood 307 
flow facilitating glucose uptake [6,15]. Given muscle blood flow may increase during PH [78] and 308 
an increase in muscle blood flow may independently facilitate glucose uptake [34], the mechanism 309 
is logical. However, the present data show that PH does not acutely benefit glycaemic control in 310 
diabetic individuals, thus not supporting the proposed mechanism. Despite this, it is important to 311 
highlight the scarcity of data investigating PH and glycaemic control and, in particular, the PH use 312 
in diabetic individuals. Based on the limited human data available and current animal models it 313 
could be hypothesised that as an individual continues PH sessions over days and weeks, basal 314 
iHSP levels rise, eHSP levels fall. Alongside the increased release of nitric oxide and glucose 315 
transporter expression, the ratio change between iHSP/eHSP associated with PH will reduce 316 
inflammatory cytokines which may improve insulin signalling to aid glycaemic control and reduce 317 
the high insulin output [39,45,50–52,79–83]. Other factors such as improved appetite regulation 318 
(i.e. increased leptin concentration) and fat mass loss have been shown to occur with PH [6,64] 319 
and may work synergistically to improve glucose homeostasis. 320 
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 321 
If an increase in iHSP is necessary for improvements in glucose homeostasis in diabetic 322 
individuals, then a sufficient heating stimulus is required. Exposure to 43 °C – 53 °C air for 60 323 
minutes increased body temperature by ≤0.5 °C [65,70], while immersion in 39 °C water for the 324 
same time increased temperature to ~38.5 °C (~1.6 °C difference versus control) [64]. A deep body 325 
temperature rise of >0.8 °C has been shown to increase eHSP concentrations [84–86], but it is 326 
unknown whether this modest rise in deep body temperature is a great enough stimulus to increase 327 
iHSP concentrations. iHSP was increased in murine models where rectal temperature was held at 328 
41.5 °C for ~20 minutes [39,53], and where human whole-blood was incubated for two hours at 329 
42 °C [52]. However, it is not ethically acceptable to maintain rectal temperature >39.5 °C in an 330 
attempt to elicit iHSP. Considering the impaired thermoregulatory control in individuals with 331 
diabetes [87], finding the lowest thermal stress required for health benefits should be a focus of 332 
future work. 333 
 334 
No adverse events were noted in the studies reported in this meta-analysis. It is possible, however, 335 
with inappropriate PH protocols such an event may occur. For example, PH increases absorption 336 
of exogenously delivered insulin which could increase the likelihood of hypoglycaemic events 337 
[72,88]. Thermal sensations and thermoregulation may also be impaired in diabetic individuals 338 
[87,89] which could lead to burns and heat-related illness. 339 
 340 
The strength of the meta-analysis presented here is that it combined data from 14 studies to 341 
estimate the effect of PH on glycaemic control with more accuracy than could be achieved in a 342 
single study. The risk of bias of the included studies appears low to unclear (Fig 2). If blinding of 343 
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the participant and outcome assessment are ignored, then the risk of bias is mostly unclear. 344 
Importantly, there was a high risk of bias in selective reporting where authors simply failed to 345 
report variables or reported only ‘good responders’ [30]. However, the main limitation of this 346 
meta-analysis was the methodological differences amongst studies, including participants (e.g. 347 
duration of diabetes, age, sex), protocols (e.g. duration and modality of heating) and outcome 348 
assessment (e.g. timing of glucose measurement). These differences increase the heterogeneity in 349 
outcome measures. To account for heterogeneity, a random-effects model was utilised in the 350 
present meta-analysis; with more research in this area future analyses will be more robust and 351 
allow subgroup analyses.  352 
 353 
In conclusion, this meta-analysis reveals an unclear picture of how PH may benefit glycaemic 354 
control in non-diabetic and diabetic humans. In non-diabetic individuals, glucose intolerance may 355 
occur when PH follows a glucose load. Importantly, however, this work highlights the paucity of 356 
research that has been conducted on this potentially beneficial, low-cost, intervention. Future 357 
research should focus on diabetic humans, using a randomised controlled trial design to measure 358 
glycaemic control in response to chronic PH. The benefits of PH may follow a dose-response 359 
relationship between the temperature and duration of heating [3]. Therefore, future work should 360 
determine the appropriate heat exposure to benefit glycaemic control in people with diabetes. If 361 
PH is found to be beneficial, then guidelines should then be developed with practical end-user 362 
constraints in mind. 363 
  364 
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